A recently conducted clinical trial has determined that treating individuals with undiagnosed chronic obstructive pulmonary disease or asthma improved their health and decreased healthcare visits for respiratory symptoms in the time they were diagnosed.
To find individuals with the undiagnosed illnesses, the scientists dialed random numbers at different sites across Canada between 2017 and 2023. During the calls, respondents were asked whether there were any persons in the house who experienced unexplained prolonged coughs, wheezing or shortness of breath, or who were coughing up mucus.
As a result of the calls, more than 26,000 individuals with these symptoms completed questionnaires.
Those who were likely to have chronic obstructive pulmonary disease (COPD) or asthma underwent a spirometry breathing test, which is usually used to diagnose these conditions. As a result, 595 individuals were then diagnosed with either condition, with about 500 agreeing to take part in a randomized controlled trial to compare the effectiveness of different types of care.
Half of the participants were treated by a COPD/asthma educator and lung specialist while the other half were randomly assigned to a primary care provider. Those who were treated by specialists were given inhalers to manage their conditions and taught how to use the devices. They were also taught how to manage flareups on their own. Additionally, they were provided with exercise, treatment to stop smoking and weight counseling, as well as flu and pneumonia vaccines when appropriate.
More than 90% of patients in this group also began taking new drugs for the aforementioned conditions, in comparison to 60% of patients who were treated by primary-care providers.
The investigators observed that patients treated by specialists averaged 0.5 healthcare visits annually for their symptoms, in comparison to 1.1 visits by those who received normal care. Additionally, those who were treated by specialists observed the average score on the St. George’s Respiratory questionnaire increase by more than 10 points. This is in comparison to the 6.8-point increase for those who received normal care. The difference in point increases points to an improvement in quality of life and overall health.
Dr. Shawn Aaron, a lung specialist at the Ottawa Hospital and lead of the study, explained that while not everyone could see a lung specialist in the real world, patients getting diagnosed and treated improved their symptoms. He noted that participants in the study, both those who went to primary care providers and those who saw specialists, experienced good outcomes, even if the outcomes did vary. In addition, he encouraged patients to advocate for themselves because this would make it easier to catch more undiagnosed cases.
The trial’s findings were reported in the “New England Journal of Medicine.”
These findings underscore how important it is to expand access to diagnostic equipment for various diseases. Many companies, such as Astrotech Corp. (NASDAQ: ASTC), are stepping up to contribute to addressing this need.
NOTE TO INVESTORS: The latest news and updates relating to Astrotech Corp. (NASDAQ: ASTC) are available in the company’s newsroom at https://ibn.fm/ASTC
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is powered by IBN